<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><?origin nihpa?><?iso-abbr Nat. Genet.?><?submitter-system nihms?><?submitter-canonical-name Nature Publishing Group?><?submitter-canonical-id NATURE-STRUCTUR?><?submitter-userid 1045?><?submitter-authority publisher?><?submitter-login nature-structure?><?submitter-name Nature Publishing Group (obsolete)?><?domain nihpa?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">9216904</journal-id><journal-id journal-id-type="pubmed-jr-id">2419</journal-id><journal-id journal-id-type="nlm-ta">Nat Genet</journal-id><journal-id journal-id-type="iso-abbrev">Nat. Genet.</journal-id><journal-title-group><journal-title>Nature genetics</journal-title></journal-title-group><issn pub-type="ppub">1061-4036</issn><issn pub-type="epub">1546-1718</issn></journal-meta><article-meta><article-id pub-id-type="pmcid">3963408</article-id><article-id pub-id-type="pmid">24413734</article-id><article-id pub-id-type="doi">10.1038/ng.2873</article-id><article-id pub-id-type="manuscript">nihpa549899</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Recurrent mutations in epigenetic regulators, <italic>RHOA</italic>and <italic>FYN</italic> kinase in peripheral T cell lymphomas</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Palomero</surname><given-names>Teresa</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A17">17</xref></contrib><contrib contrib-type="author"><name><surname>Couronn&#x000e9;</surname><given-names>Lucile</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A17">17</xref></contrib><contrib contrib-type="author"><name><surname>Khiabanian</surname><given-names>Hossein</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A17">17</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Mi-Yeon</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ambesi-Impiombato</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Perez-Garcia</surname><given-names>Arianne</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Carpenter</surname><given-names>Zachary</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Abate</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Allegretta</surname><given-names>Maddalena</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Haydu</surname><given-names>J. Erika</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Xiaoyu</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lossos</surname><given-names>Izidore S.</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Nicolas</surname><given-names>Concha</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Balbin</surname><given-names>Milagros</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Bastard</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Bhagat</surname><given-names>Govind</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Piris</surname><given-names>Miguel Angel</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Campo</surname><given-names>Elias</given-names></name><xref ref-type="aff" rid="A11">11</xref><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Bernard</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="A13">13</xref><xref ref-type="aff" rid="A14">14</xref><xref ref-type="aff" rid="A15">15</xref></contrib><contrib contrib-type="author"><name><surname>Rabadan</surname><given-names>Raul</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ferrando</surname><given-names>Adolfo</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A16">16</xref></contrib></contrib-group><aff id="A1"><label>1</label>Institute for Cancer Genetics, Columbia University, New
York, NY, USA.</aff><aff id="A2"><label>2</label>Department of Pathology, Columbia University Medical
Center, New York, NY, USA.</aff><aff id="A3"><label>3</label>Joint Centers for Systems Biology, Columbia University, New
York, NY, USA.</aff><aff id="A4"><label>4</label>Department of Control and Computer Engineering, Politecnico
di Torino, Torino, Italy</aff><aff id="A5"><label>5</label>Division of Hematology -Oncology, Sylvester Comprehensive
Cancer Center, Miami, FL, USA.</aff><aff id="A6"><label>6</label>Department of Molecular and Cellular Pharmacology,
University of Miami, Miami, FL, USA.</aff><aff id="A7"><label>7</label>Hematology Service, Hospital Central de Asturias, Oviedo,
Spain.</aff><aff id="A8"><label>8</label>Molecular Oncology Laboratory, Instituto Universitario de
Oncologia del Principado de Asturias, Hospital Universitario Central de Asturias,
Oviedo, Spain.</aff><aff id="A9"><label>9</label>INSERM U918 Centre Henri Becquerel, Rouen, France.</aff><aff id="A10"><label>10</label>Pathology Department, Hospital Universitario Marques de
Valdecilla, Santander, Spain.</aff><aff id="A11"><label>11</label>Hematopathology Section, Department of Pathology,
Hospital Clinic, Barcelona, Spain.</aff><aff id="A12"><label>12</label>Institut d'Investigacions Biom&#x000e8;diques August Pi i
Sunyer, University of Barcelona, Barcelona, Spain.</aff><aff id="A13"><label>13</label>INSERM, U985; Villejuif 94805, France.</aff><aff id="A14"><label>14</label>Universit&#x000e9; Paris-Sud, Orsay 91400, France.</aff><aff id="A15"><label>15</label>Institut Gustave Roussy, Villejuif 94805, France.</aff><aff id="A16"><label>16</label>Department of Pediatrics, Columbia University Medical
Center, New York, NY, USA.</aff><aff id="A17"><label>17</label>These authors contributed equally to this work</aff><author-notes><corresp id="CR1">Correspondence should be addressed to A.F.
(<email>af2196@columbia.edu</email>), R.R.
(<email>rabadan@dbmi.columbia.edu</email>) and T.P.
(<email>tp2151@columbia.edu</email>).</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>29</day><month>1</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>12</day><month>1</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>8</month><year>2014</year></pub-date><volume>46</volume><issue>2</issue><fpage>166</fpage><lpage>170</lpage><!--elocation-id from pubmed: 10.1038/ng.2873--><permissions><license><license-p>Users may view, print, copy, download and text and data- mine the
content in such documents, for the purposes of academic research, subject
always to the full Conditions of use: <uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p></license></permissions><abstract><p id="P1">Peripheral T-cell lymphomas (PTCLs) are a heterogeneous and poorly
understood group of non Hodgkin lymphomas<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup>. Here we
combined whole exome sequencing of 12 tumor-normal DNA pairs, RNAseq analysis
and targeted deep sequencing to identify new genetic alterations in PTCL
transformation. These analyses identified highly recurrent epigenetic factor
mutations in <italic><bold>TET2, DNMT3A </bold></italic><bold>and
</bold><italic><bold>IDH2 </bold></italic><bold>as well as a new highly
prevalent </bold><italic><bold>RHOA</bold></italic> p.Gly17Val (NM_001664)
mutation present in 22/35 (67%) of angioimmunoblastic T-cell lymphomas (AITL)
and in 8/44 (18%) not otherwise specified PTCL (PTCL NOS) samples.
Mechanistically, the RHOA Gly17Val protein interferes with RHOA signaling in
biochemical and cellular assays, an effect potentially mediated by the
sequestration of activated Guanine Exchange Factor (GEF) proteins. In addition,
we describe new and recurrent, albeit less frequent, genetic defects including
mutations in <italic><bold>FYN, ATM, B2M </bold></italic><bold>and
</bold><italic><bold>CD58</bold></italic> implicating SRC signaling,
impaired DNA damage response and escape from immune surveillance mechanisms in
the pathogenesis of PTCL.</p></abstract></article-meta></front><body><p id="P2">To investigate the genetics and pathogenic mechanisms of aggressive PTCLs we
performed whole exome sequencing of matched tumor and normal DNA from 12 PTCL patients
including 6 PTCL-NOS cases, 3 AITLs and 2 nasal type NK-/T-cell lymphomas and 1
enteropathy associated T-cell lymphoma (<bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Tables 1 and 2</xref></bold>). This analysis identified
a mean of 24 non synonymous somatic mutations per sample (range 4 &#x02013; 57)
(<bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Table
1</xref></bold>). A total of 288 candidate coding somatic mutations in 268 genes
were identified. These included five mutant alleles in the <italic>TET2</italic> tumor
suppressor, three alleles in the <italic>SETD2</italic> and <italic>DNAH5</italic> and
two in the <italic>TACC2</italic>, <italic>RYR3, PTPRD</italic> and
<italic>MGAT4C</italic> genes (<bold><xref ref-type="supplementary-material" rid="SD2">Supplementary Tables 3</xref></bold> and <bold><xref ref-type="supplementary-material" rid="SD1">4</xref></bold>). In addition
we identified a recurrent heterozygous mutation in the <italic>RHOA</italic> small
GTPase gene (p.Gly17Val) present in two independent AITLs and one PTCL NOS sample
(<bold><xref ref-type="fig" rid="F1">Fig. 1a</xref></bold> and <bold><xref ref-type="supplementary-material" rid="SD2">Supplementary Tables 3</xref></bold>
and <bold><xref ref-type="supplementary-material" rid="SD1">4</xref></bold>). These
results were confirmed and extended by deep sequencing analysis of 125 PTCL DNAs, which
showed the presence of the recurrent <italic>RHOA</italic> p.Gly17V mutation and
detected several additional <italic>RHOA</italic> mutations (p.Cys16Arg, p.Thr19Ile,
p.Gly17Glu and p.Asp120Tyr) present in a single case each (<bold><xref ref-type="fig" rid="F1">Fig. 1a</xref></bold> and <bold><xref ref-type="supplementary-material" rid="SD2">Supplementary Table 5</xref></bold>). Notably the frequency of the
allele encoding the Gly17Val alteration correlated with the proportion of tumor cells in
PTCL biopsies as evaluated by multicolor flow cytometry (<bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Figure
1</xref></bold>), supporting that the variable and frequently low proportion of reads
harboring this mutation in many PTCLs may be primarily the result of the low tumor
content in these samples. Thus, and to best assess the actual prevalence of
<italic>RHOA</italic> p.Gly17Val alteration in our series we reanalyzed this panel
using a highly sensitive (1:1,000) allele specific PCR mutation assay. Using this
approach we detected the presence of the allele encoding the Gly17Val mutant RHOA in 30
samples including 22/35 (67%) AITLs and 8/44 (18%) PTCL NOS tumors analyzed (AITL
<italic>vs.</italic> all other PTCLs: <italic>P</italic> &#x0003c; 0.001; PTCL NOS
<italic>vs.</italic> non-AITL non-PTCL NOS: <italic>P</italic> &#x0003c; 0.002; AITL
<italic>vs.</italic> PTCLs NOS: <italic>P</italic> &#x0003c; 0.001) (<bold><xref ref-type="fig" rid="F1">Fig. 1b,c</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2</xref></bold>
and <bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Table
6</xref></bold>).</p><p id="P3">RHOA belongs to the Rho family of small GTPases, a group of Ras-like proteins
responsible for linking a variety of cell-surface receptors to different intracellular
signaling proteins<sup><xref rid="R3" ref-type="bibr">3</xref>-<xref rid="R5" ref-type="bibr">5</xref></sup>. As is the case for RAS and most other small GTPases,
RHOA cycles between inactive &#x02013; GDP-bound&#x02013; and active
&#x02013;GTP-bound&#x02013; configurations<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup>, a molecular switch
strictly controlled by the GTP loading activity of guanosine exchange factor proteins
(GEFs)<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup>. In its active configuration, GTP RHOA interacts with
multiple downstream effectors that control the structure and dynamics of the actin
cytoskeleton and the formation of stress fibers<sup><xref rid="R6" ref-type="bibr">6</xref></sup>. Given the recurrent nature of the <italic>RHOA</italic>
pGly17Val mutation we postulated that this allele could represent a gain of function
mutation with either constitutively active or dominant negative activity.</p><p id="P4">The RHO-family of GTPases, including RHOA, regulates actin cytoskeleton and cell
adhesion and is implicated in cell polarization in multiple cell types<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup>.
Thus, in order to explore the functional effects of RHOA Gly17Val we analyzed the
changes in fibroblast cell morphology induced by expression of GFP-RHOA wild type,
constitutively active GFP-RHOA Gln63Leu<sup><xref rid="R8" ref-type="bibr">8</xref>-<xref rid="R11" ref-type="bibr">11</xref></sup>, dominant negative
GFP-RHOA Thr19Asn<sup><xref rid="R10" ref-type="bibr">10</xref>-<xref rid="R12" ref-type="bibr">12</xref></sup> and GFP-RHOA Gly17Val fusions. Activation of RHOA
signaling triggered by GFP-RHOA overexpression and most prominently by the
constitutively active GFP-RHOA Gln63Leu induced loss of adhesion and round cell
morphology in HEK293T cells (<bold><xref ref-type="fig" rid="F2">Fig. 2a</xref></bold>).
In contrast, cells expressing GFP-RHOA Gly17Val mimicked the phenotype of fibroblasts
expressing dominant negative GFP-RHOA Thr19Asn, which showed increased elongated
morphology and cellular protrusions (<bold><xref ref-type="fig" rid="F2">Fig.
2a</xref></bold>). Similarly, immunofluorescence analysis of F-actin in HeLa cells
showed increased stress fiber formation in cells expressing GFP-RHOA, which was markedly
accentuated upon constitutive activation of RHOA signaling triggered by the GFP-RHOA
Gln63Leu mutant (<bold><xref ref-type="fig" rid="F2">Fig. 2b</xref></bold>). On the
other hand, cells expressing GFP-RHOA Gly17Val or GFP-RHOA Thr19Asn showed decreased
F-actin stress fibers, which is consistent with an inhibitory role of these mutations in
RHO signaling (<bold><xref ref-type="fig" rid="F2">Fig. 2b</xref></bold>).</p><p id="P5">Following on these results, we expressed HA-tagged forms of wild type RHOA and
RHOA Gly17Val in Jurkat T-cells and tested their capacity to interact with rhotekin, an
effector protein that specifically recognizes the active GTP-bound form of
RHOA<sup><xref rid="R13" ref-type="bibr">13</xref></sup>. Rhotekin pull down
analysis showed significant activation of HA-RHOA in Jurkat cells in basal conditions,
which was further increased upon serum stimulation (<bold><xref ref-type="fig" rid="F2">Fig. 2c</xref></bold>). In contrast, rhotekin failed to interact with HA-RHOA
Gly17Val (<bold><xref ref-type="fig" rid="F2">Fig. 2c</xref></bold>). Similarly,
rhotekin did not interact with dominant negative HA-RHOA Thr19Asn, while the
constitutively active HA-RHOA Gln63Leu protein showed marked increased rhotekin binding
(<bold><xref ref-type="fig" rid="F2">Fig. 2c</xref></bold>). Given that rhotekin
selectively binds to the GTP-bound form of RHOA, we hypothesized that RHOA Gly17Val is
locked in an inactive configuration devoid of GTP. Indeed, a highly related RHOA
Gly17Ala mutant protein capable of interacting with GEF proteins with high affinity, but
resistant to GEF-induced GTP loading and activation has been described <sup><xref rid="R14" ref-type="bibr">14</xref></sup>. To test this hypothesis, we analyzed
the capacity of GSTRHOA, GST-RHOA Gly17Val and GST-RHOA Gly17Ala recombinant proteins to
bind to GTP in response to MCF2L/DBS GEF stimulation <italic>in vitro</italic> using a
fluorescence polarization assay. As expected, MCF2L/DBS triggered the loading of a
fluorescent GTP analog (mant-GTP) into GST-RHOA (<bold><xref ref-type="fig" rid="F2">Fig
2d</xref></bold>). However, GST-RHOA Gly17Ala and GST-RHOA Gly17Val were
resistant to the activity of this GEF factor (<bold><xref ref-type="fig" rid="F2">Fig.
2d</xref></bold>). Finally, we tested if RHOA Gly17Val could function as a high
affinity GEF trap analogous to RHOA Gly17Ala sequestering activated GEF proteins in
T-cells. GST pull down assays against ARHGEF1, a GEF factor highly expressed in T-cells,
showed increased affinity of GST RHOA Gly17Val and most markedly GST-RHOA Gly17Ala
compared to GST-RHOA wild type (<bold><xref ref-type="fig" rid="F2">Fig.2e</xref></bold>). Overall, these results are consistent with an inhibitory role
for RHOA Gly17Val in RHO signaling potentially mediated by the sequestration of GEF
factors and support a role for disruption of RHOA signaling in the pathogenesis of
PTCLs.</p><p id="P6">Next, and to more broadly assess the presence of recurrent genetic alterations
and fusion oncogenes in PTCL we analyzed a cohort of 34 lymphoma samples by RNAseq
(<bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Table
7</xref></bold>). This analysis identified 4 samples harboring
<italic>ALK</italic> fusion transcripts (3 <italic>NPM-ALK</italic> and 1
<italic>TFG-ALK</italic>), all corresponding to ALCL cases (<bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Table
8</xref></bold>). In addition we detected the presence of candidate recurrent mutations
in <italic>TET2, DNMT3A</italic> and <italic>IDH2</italic> and identified additional
potential drivers of PTCL transformation (<bold><xref ref-type="supplementary-material" rid="SD2">Supplementary Table 9</xref></bold>). Deep sequencing analysis of
these and additional selected candidate genes including FYN, TET3, CDKN2A, PRKD2, RHOT2,
SMARCAL1, ATM, B2M and <italic>CD58</italic> in an extended panel of 125 PTCL DNAs
including those analyzed by RNAseq showed a prominent role of mutations targeting DNA
methylation and hydroxymethylation (<italic>TET2, DNMT3A, IDH2</italic> and
<italic>TET3</italic>) as shown before<sup><xref rid="R15" ref-type="bibr">15</xref>-<xref rid="R17" ref-type="bibr">17</xref></sup> and highlighted the
role of defective DNA damage response (<italic>ATM</italic>) and escape from T-cell and
NK cell immune surveillance (<italic>B2M</italic> and <italic>CD58</italic>) in the
pathogenesis of PTCL (<bold><xref ref-type="fig" rid="F3">Fig. 3b</xref></bold> and
<bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Table
5</xref></bold>). In addition, we detected the presence of new recurrent
<italic>FYN</italic> kinase (NM_002037) mutations including a recurrent allele
encoding a p.Arg176Cys substitution present in two PTCL NOS cases, a mutation encoding a
p.Leu174Arg alteration found in one AITL patient sample, in addition to the p.Tyr531His
encoding allele identified via exome analysis in a PTCL NOS sample for an overall
frequency of 3% (4/137) <italic>FYN</italic> mutations in our series (<bold><xref ref-type="fig" rid="F3">Fig. 3b</xref></bold> and <bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Table
5</xref></bold>).</p><p id="P7">The FYN tyrosine kinase is, with LCK, the predominant SRC family kinase found in
T lymphocytes and plays an important role in T-cell activation upon T-cell receptor
(TCR) stimulation<sup><xref rid="R18" ref-type="bibr">18</xref></sup>. Strikingly,
<italic>FYN</italic> mutations found in PTCL are predicted to specifically disrupt
the intramolecular inhibitory interaction of the FYN SH2 domain with C-terminal SRC
kinase (CSK) phosphorylated FYN Tyr531. Consistently, expression of FYN Leu174Arg, FYN
Arg176Cys and FYN Tyr531His in Rat1A cells resulted in increased levels of FYN
activation compared with control cells expressing wild type FYN (<bold><xref ref-type="fig" rid="F4">Fig. 4a,b</xref></bold>). In addition, structure model
analysis of FYN and FYN mutant proteins further supported this hypothesis (<bold><xref ref-type="fig" rid="F4">Fig. 4c,d</xref></bold>). To test this model, we
analyzed the interaction between GST-FYN-SH2 recombinant proteins and biotinylated
C-terminal FYN peptides encompassing the position Tyr531. In these assays, wild type
GST-FYNSH2 was effectively pulled down with a Tyr531 phosphopeptide, but not with the
corresponding unphosphorylated sequence or with a peptide containing a Tyr531His
substitution (<bold><xref ref-type="fig" rid="F4">Fig. 4e</xref></bold>). Similarly, the
introduction of a Leu174Arg or a Arg176Cys substitution abrogated the interaction of
GST-FYN-SH2 with the phospho-Y531 FYN C-terminal peptide (<bold><xref ref-type="fig" rid="F4">Fig. 4f</xref></bold>). Consistently, CSK effectively inhibited wild
type FYN, but failed to abrogate the activity of the FYN mutant proteins (<bold><xref ref-type="fig" rid="F4">Fig. 4g</xref></bold>). Finally, given the prominent
role of kinase inhibitors as targeted therapies for tumors driven by constitutively
active kinase oncogenes, we tested the capacity of dasatinib, a multikinase inhibitor
which blocks ABL1 and SRC kinases<sup><xref rid="R19" ref-type="bibr">19</xref></sup>,
to inhibit the activity of FYN Leu174Arg, FYN Arg176Cys and FYN Tyr531His mutant
proteins. Notably, in each case, dasatinib treatment induced dose dependent inhibition
of FYN phosphorylation (<bold><xref ref-type="fig" rid="F4">Fig. 4h</xref></bold>).
Moreover, dasatinib treatment impaired the growth of transformed Rat1A cells expressing
the FYN Tyr531His mutant protein, but not that of cells expressing a drug-resistant
gatekeeper mutant form of this kinase (FYN Thr342Ile Tyr531His) (<bold><xref ref-type="fig" rid="F4">Fig. 4i,j</xref></bold>). Based on these results we
propose that SRC kinase inhibition with dasatinib may confer a therapeutic benefit in
selected PTCL cases harboring activating mutations in the <italic>FYN</italic> kinase
gene.</p><sec sec-type="methods" id="S1" specific-use="web-only"><title>METHODS</title><sec id="S2"><title>Patient samples</title><p id="P8">DNAs from PTCLs were provided by tumor banks at Columbia University
Medical Center in New York, USA; Sylvester Comprehensive Cancer Center, Miami,
USA; Hospital Central de Asturias in Oviedo, Spain; Centro Nacional de
Investigaciones Oncologicas in Madrid, Spain; Institut Gustave Roussy,
Villejuif, France; Centre Henri Becquerel, Rouen, France; and Hospital Clinic in
Barcelona, Spain. Samples were obtained with informed consent and analysis was
conducted under the supervision of the Columbia University Medical Center
Institutional Review Board. We selected samples for Whole Exome Sequencing based
on the availability of sufficient DNA from diagnosis, and normal (blood, buccal
swab or non tumor infiltrated biopsy material) matched samples.</p></sec><sec id="S3"><title>Whole exome capture and nextgen sequence analysis</title><p id="P9">We used matched tumor and normal DNA samples from 12 PTCL patients
(<bold><xref ref-type="supplementary-material" rid="SD1">Supplementary
Table 1</xref></bold>) for exome capture with the SureSelect 50 Mb All
Exon kit (Agilent Technologies) following standard protocols. We performed
paired-end sequencing (2 &#x000d7; 100 bp) using HiSeq2000 sequencing instruments
at Centrillion Biosciences (Palo Alto, CA). Illumina HiSeq analysis produced
between 67.5 and 136.8 million paired-end reads per sample (<bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Table
2</xref></bold>). We mapped reads to the reference genome hg19 using the
Burrows-Wheeler Aligner (BWA) alignment tool version 0.5.9. Mean depth (defined
as mean number of reads covering the captured coding sequence of a haploid
reference) was 45x with 84% of the genome covered more than 10&#x000d7; and 58%
covered more than 30&#x000d7;. We identified sites that differ from reference
(called here variants) in each sample independently. We constructed empirical
priors for the distribution of variant frequencies for each sample. We obtained
high-credibility intervals (posterior probability &#x02265;
1&#x02013;10<sup>&#x02212;5</sup>) for the corresponding change in frequency
between tumor and normal samples, using the SAVI algorithm (Statistical
Algorithm for Variant Identification) developed at Columbia University<sup><xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R33" ref-type="bibr">33</xref></sup>. The number of germline SNPs in the coding region were
18,000 comparable with previous reports<sup><xref rid="R32" ref-type="bibr">32</xref></sup>. Most of the candidate germline SNPs (16,000, or
~90% of germline variants) were reported in dbSNP database. We identified
candidate somatic variants using the following criteria: variant total depth in
tumor and normal larger than 10&#x000d7; and smaller than 300&#x000d7;, variant
frequency larger than 15% in tumor and less than 3% in normal, and at least 1%
change in frequency from the normal with high posterior probability (&#x02265;
1&#x02013;10<sup>&#x02013;5</sup>). Also to remove systematic errors, we
excluded all variants that were found present in any of the normal cases. In
addition, to eliminate ambiguous mapping from captured pseudogenes, and regions
of low complexity, each variant with a flanking 20-base context sequence around
its genomic position was mapped to the hg19 reference using the BLAST algorithm.
We kept in the list only those with unique mappability, i.e. we required the
41-base sequence to uniquely map to the reference genome, with only one
mismatch.</p></sec><sec id="S4"><title>Mutation validation</title><p id="P10">We designed primers flanking exons containing 121 randomly selected
candidate somatic variants identified by exome sequencing using Primer3, and
used Whole-Genome-Amplified (WGA) DNA from tumor and matched normal DNAs for PCR
amplification. We analyzed the resulting amplicons by direct bidirectional
dideoxynucleotide sequencing and obtained a validation rate of 90% (<bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Table
1</xref></bold>).</p></sec><sec id="S5"><title>RNA Sequencing, mapping, and identification of variants</title><p id="P11">After the exome sequence analysis of 12 tumor and normal PTCL samples
(<bold><xref ref-type="supplementary-material" rid="SD1">Supplementary
Table 1</xref></bold>); we analyzed 34 additional PTCL samples by
RNA-Seq using paired-end Illumina Hiseq sequencing. (<bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Table
7</xref></bold>). We obtained on average over 67.6 million reads, 51.5
million (75.7%) mapped to the human NCBI reference sequence (RefSeq) using BWA
alignment algorithms<sup><xref rid="R20" ref-type="bibr">20</xref></sup>. Reads
mapping on the same starting position were discarded. We identified sites that
differed from the reference in each sample and constructed empirical priors for
the distribution of variant frequencies for each sample independently. In order
to reduce the false positive rate in variants detection and remove mapping
artifacts and systematic errors, we mapped samples&#x02019; paired-end reads to
human RefSeq with Bowtie2 alignment algorithm<sup><xref rid="R21" ref-type="bibr">21</xref></sup>, which mapped a total of 1.83 billion reads of
reads (76%) properly to the reference. We then identified sites that differed
from the reference in each sample and intersected the set of variants identified
with both BWA and Bowtie2 alignments as previously described<sup><xref rid="R22" ref-type="bibr">22</xref></sup>. In all samples, we selected
variants with total depth &#x0003e;10&#x000d7; and frequency &#x0003e;20%, and
excluded variants identified in dbSNP135 database, as well as those which did
not pass the Multiplicity filter. In addition, variants corresponding to poorly
expressed (RPKM &#x0003c; 3) genes were removed to reduce the effects of spurious
PCR amplification during library preparation. In order to reduce the presence of
germline mutations, variants identified also present in 65 DNA-Seq samples from
unaffected individuals were excluded and we removed also variants common to
those present in 11 RNASeq samples from normal B and T cells. In detail, we
mapped the normal RNA-Seq sample reads with BWA and Bowtie to human RefSeq and
identified the variants, creating an internal normal variant database (INVD)
composed by the union of all the variants identified in normal B and T cells.
Successively, we filtered those variants occurring in PTCL samples overlapping
the INVD. Finally, we limited the list of variants to those identified in genes
found somatically mutated in PTCL by exome sequencing.</p></sec><sec id="S6"><title>Targeted deep resequencing</title><p id="P12">Mutational analysis of selected genes of interest was performed by
targeted resequencing using microfluidics PCR (Access Array system; Fluidigm)
followed by sequencing of the amplicon libraries in a MiSeq instrument
(Illumina). Primers targeting the regions of interest were designed at Fluidigm
to produce amplicons of 200 bp &#x000b1; 20 bp. We performed multiplex PCR
amplification of up to 10 amplicons per well in the Fluidigm Access Array chip
according to the manufacturer's instructions using 30 ng of DNA per sample.
After multiplex PCR amplification the resulting DNA products were barcoded so
that all amplicons corresponding to the one sample carry the same index. Indexed
libraries were pooled and the resulting library was quantified by quantitative
PCR using the Kapa Library Quantification Kit (Kapa Biosystems) in a 7500 PCR
instrument (Applied Biosystems). Amplicon libraries were spiked with ~25%
PhiX genomic library to increase amplicon diversity and sequenced in a MiSeq
instrument to generate 2&#x000d7;251 bp paired reads following an amplicon
sequencing protocol for custom primers. Each pair of the paired end reads
produced by MiSeq were stitched together using FLASH version 1.2.6 (Fast Length
Adjustment of SHort reads), given that the amplicon sequences (up to 200 bp)
were shorter than the read length (251 bp). This step increases the quality of
the reads correcting for mismatches in the overlap by selecting the base with
higher quality. Then, 5' and 3' adaptors and PCR primer sequences, were trimmed
using cutadapt. Merged and trimmed reads were aligned to the UCSC hg19 reference
genome using BWA-MEM as single-end reads. Aligned reads were analyzed for
variants using the SAVI (Statistical Algorithm for Variant Identification)
algorithm and variants were selected based on coverage depth and frequency.
Given the presence of significant normal cells in most PTCL samples, variants
around 50% frequency were flagged as candidate private germline SNPs. Candidate
variants identified by this first round of amplicon resequencing were
independently validated in a second round of targeted deep sequencing. Briefly,
we selectively amplified the amplicons covering the positions of candidate
mutations in their corresponding positive samples, barcoded these PCR products,
pooled them and sequenced the resulting library in a MiSeq instrument as
detailed before.</p></sec><sec id="S7"><title>RNAseq gene fusion analysis</title><p id="P13">We performed gene fusion analysis in RNAseq data using ChimeraScan
<sup><xref rid="R23" ref-type="bibr">23</xref></sup> and deFuse
<sup><xref rid="R24" ref-type="bibr">24</xref></sup> algorithms, which
identify gene fusion candidates by detecting read pairs discordantly mapping to
two different genes. From this analysis we then successively reduced the
candidate list by applying homology-based filters and by detecting reads
spanning across the junction breakpoint (Split Reads). Finally, we annotated
candidate fusions on the base of the breakpoint coordinates, predicted amino
acid sequence, open reading frame conservation and UniProt database proteomic
information.</p></sec><sec id="S8"><title>Quantitative <italic>RHOA</italic> p.Gly17Val allele specific qPCR
assay</title><p id="P14">Analysis and quantitation of <italic>RHOA</italic> p.Gly17Val was
performed using a Mutation Detection Assay Competitive Allele-Specific
TaqMan&#x000ae; PCR (Life Technologies) following the manufacturer's instructions
with slight modifications. All analyses were conducted on a 7500 real-time PCR
system run with 7500 software (v.2.0.6 Applied Biosystems). The assay was run in
96-well plates in a reaction volume of 20 &#x003bc;L, using 50 ng of genomic DNA,
10 &#x003bc;L of Taqman Universal PCR Master Mix 2x, and 2 &#x003bc;L of specific
Taqman assay 10&#x000d7; (<italic>RHOA</italic> wild type or
<italic>RHOA</italic> p.Gly17Val). We used a thermal profile of 10 min at
95&#x000b0;C for Hot Gold Start activation followed by 40 cycles of amplification
(95&#x000b0;C for 15 s and 55&#x000b0;C for 60 s). The threshold detection was set
at 0.05. Standard curves of C<sub>T </sub><italic>vs.</italic> log template
amount for each specific assay were linear over the range of 25 to 250,000
copies of plasmid DNA. We determined a sensitivity of detection for the
<italic>RHOA</italic> p.Gly17Val mutant allele assay of &#x0003c;0.1% by
analyzing samples consisting of 10, 25, 10<sup>2</sup> and 10<sup>3</sup> copies
of <italic>RHOA</italic> p.Gly17Val mutant allele plasmid DNA spiked into 30 ng
(10<sup>4</sup> copies) of wild type genomic DNA, which corresponds to
samples containing 0.1%, 0.25%, 1% or 10% mutation load, respectively. Data
analysis was performed with the Mutation Detector&#x02122; Software (Life
Technologies). Briefly, in mutation analysis calculations, the difference
between the C<sub>T</sub> value of the mutant allele assay and the C<sub>T</sub>
value of the wild type allele assay is calculated for all mutant allele assays
run on the sample. This &#x00394;C<sub>T</sub> value represents the quantity of
the specific mutant allele detected within the sample and is used to determine
the sample mutation status by comparison to a predetermined detection
&#x00394;C<sub>T</sub> cutoff value.</p></sec><sec id="S9"><title>Structural depiction and analysis</title><p id="P15">We identified structural coverage of the FYN protein through use of the
PSI-Blast and SKAN algorithms. The structures 2DQ7, 2DLY, 3UA7, 2LP5, and 1G83
were structurally aligned into composite structures to assess for conformational
flexibilities, and subsequently analyzed through use of the Chimera
Suite<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup>. In silico modeling of
identified mutations was performed using the I-TASSER software suite and
Modeller program; structures were refined and analyzed in Chimera<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup>. We predicted protein stability changes upon mutation
through use of the SDM potential energy statistical algorithm and associated
software<sup>37</sup>. We created all structural images using UCSF
Chimera<sup><xref rid="R25" ref-type="bibr">25</xref></sup>.</p></sec><sec id="S10"><title>Plasmids and vectors</title><p id="P16">We obtained pcDNA3 EGFP-RHOA WT (plasmid#12965) containing the full
length human RHOA construct fused to EGFP as well as pcDNA3 EGFP-RHOA Thr19Asn
dominant negative (plasmid #12967) and pcDNA3 EGFP-RHOA Gln63Leu constitutively
active mutants (plasmid #12968) from Addgene, Inc<sup><xref rid="R28" ref-type="bibr">28</xref></sup>. We generated the <italic>RHOA</italic>
p.Gly17Val allele by site directed mutagenesis on the mammalian expression
pcDNA3 EGFPRHOA WT using the QuickChange II XL Site-Directed Mutagenesis Kit
(Stratagene) according to the manufacturer's instructions. We cloned PCR
products encompassing wild type <italic>RHOA</italic>, <italic>RHOA</italic>
p.Gly17Val, <italic>RHOA</italic> p.Thr19Asn and <italic>RHOA</italic>
p.Gln63Leu with an N-terminal HA tag as
<italic>BglII</italic>-<italic>XhoI</italic> fragments into the pMSCV vector
for retroviral expression. We obtained pRK5 c-FYN plasmid containing a full
length <italic>FYN</italic> open reading frame<sup><xref rid="R29" ref-type="bibr">29</xref></sup> from Addgene, Inc. (Plasmid #16032) and
introduced <italic>FYN</italic> p.Leu174Arg, <italic>FYN</italic>
p.Arg176Cys<italic>, FYN</italic> p.Tyr531His and <italic>FYN</italic>
p.Thr342Ile Tyr531His mutations using the QuickChange II XL Site-Directed
Mutagenesis Kit (Stratagene). All constructs were verified by sequencing. Wild
type and mutant FYN cDNAs containing an N-terminal HA tag were subcloned into
pcDNA3.1(&#x02013;) and into the MSCV240-puromycine-IRES-GFP retroviral vector.
The CSK-pcDNA3.1 (+) hygro plasmid expressing a full length CSK cDNA open
reading frame was a gift from Dr. Xin-Yun Huang (Cornell University, New York,
NY). We cloned FYN SH2 domain complementary DNA constructs encoding wild type
FYN SH2 domain (codons 148-231) with an N-terminal GST tag in the pGEX4-T1
expression vector between the <italic>EcoRI</italic> and <italic>XhoI</italic>
restriction sites. We generated the FYN SH2 domain mutations Leu174Arg and
Arg176Cys by site-directed mutagenesis on the <italic>E. coli</italic>
expression pGEX4-T1 FYN SH2 domain vector using the QuikChange II XL
Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer's
instructions.</p></sec><sec id="S11"><title>Cell lines</title><p id="P17">We cultured HEK293T (Thermo Scientific), HeLa (ATCC) and Rat1A cells (a
gift from Dr. Ana Lasorella, Columbia University) in DMEM media supplemented
with 10% fetal bovine serum, 100 U ml<sup>&#x02013;1</sup> penicillin G and 100
&#x003bc;g ml<sup>&#x02013;1</sup> streptomycin at 37&#x000b0;C in a humidified
atmosphere under 5% CO<sub>2</sub>. We maintained Jurkat cells (ATCC) under
similar conditions in RPMI 1640 media supplemented with 10% fetal bovine serum.
Cell lines were regularly tested for mycoplasma contamination.</p></sec><sec id="S12"><title>Retroviral production and infection</title><p id="P18">We transfected the retroviral constructs pMSCV-HARHOA, pMSCV-HA-RHOA
Gly17Val, pMSCV-HA-RHOA Gln63Leu, pMSCV-HA-RHOA Thr19Asn, pMSCV-FYN, pMSCV-FYN
Tyr531His, pMSCV-FYN Thr342Ile Tyr531His, pMSCVFYN Arg176Cys, pMSCV-FYN
Leu174Arg and the pMSCV control plasmid with gag-pol and VSVG expressing vectors
into HEK293T cells using JetPEI transfection reagent (Polyplus). We collected
viral supernatants after 48h and used them for infection of Rat1A and Jurkat
cells by spinoculation. After infection, we selected cells for 4 days in media
containing 1 &#x003bc;g/ml of puromycin.</p></sec><sec id="S13"><title>Western blot</title><p id="P19">Western blot analysis were performed using standard procedures with the
following antibodies: RHOA (67B9) rabbit monoclonal antibody against RHOA
(#2117, Cell Signaling Technology)<sup><xref rid="R30" ref-type="bibr">30</xref></sup>; FYN rabbit polyclonal antibody (#4023, Cell Signaling
Technology)<sup><xref rid="R31" ref-type="bibr">31</xref></sup>;
Phospho-Src Family (Tyr416) polyclonal antibody (#2101, Cell Signaling
Technology)<sup><xref rid="R32" ref-type="bibr">32</xref></sup>; CSK
(CSK-04) mouse monoclonal antibody (sc-51580, Santa Cruz Biotechnology); GST
mouse monoclonal antibody (clone DG122-2A7, Millipore,
1DB-001-0000851588)<sup><xref rid="R33" ref-type="bibr">33</xref></sup>;
GAPDH goat polyclonal antibody (sc-20357, Santa Cruz Biotechnology)<sup><xref rid="R34" ref-type="bibr">34</xref></sup>; ARGHEF1 goat polyclonal
antibody (sc-8492, Santa Cruz Biotechnology)<sup><xref rid="R35" ref-type="bibr">35</xref></sup> and a rat monoclonal antibody specific for HA tag
(11867423001, Roche Diagnostics, 1DB-001-0000868977).</p></sec><sec id="S14"><title>Immunofluorescence</title><p id="P20">We analyzed F-actin in Hela cells transfected with plasmids expressing
GFP, GFP-RHOA, GFP-RHOA Gln63Leu, GFP-RHOA Thr19Asn and GFP-RHOA Gly17Val by
Phalloidin Texas Red staining (1:100; Life Technologies), followed by DAPI
(4',6-Diamidino-2-Phenylindole, Dihydrochloride) staining and confocal
microscopy on a Zeiss LSM510-NLO microscope.</p></sec><sec id="S15"><title>RHOA protein expression in <italic>Escherichia coli</italic>, purification,
and GEF exchange assay</title><p id="P21">We expressed wild type RHOA, RHOA Gly17Ala and RHOA Gly17Val proteins as
GST-tagged proteins in <italic>E. coli</italic> Rosetta 2(DE3) cells. We induced
expression of the fusion proteins in bacteria cells with 0.1 mM
isopropyl-&#x003b2;-D-thiogalactopyranoside (IPTG) for 16h at 18&#x000b0;C. We
harvested cells and lysed them in lysis buffer (20 mM Hepes, pH 7.5, 150 mM
NaCl, 5mM MgCl2, 1 mM DTT, 1% Triton X-100, 0.5 mg / ml lysozyme) supplemented
with Complete EDTA-free protease inhibitor (Roche). We purified GST-tagged RHOA
proteins by binding them to immobilized glutathione Sepharose beads (Thermo
scientific) and eluting them with 50 mM reduced Glutathione, 50 mM HEPES, pH
7.4, 150 mM NaCl, 5 mM MgCl<sub>2</sub>, 5 % glycerol, 1 mM DTT. We assessed
protein expression and purity by Coomassie staining. Next, we analyzed the
capacity of purified recombinant GST-RHOA, GST-RHOA Gly17Ala and GST-RHOA
Gly17Val proteins to incorporate GTP in response to recombinant MCF2L/DBS-His
(Cytoskeleton, Inc.) with the RhoGEF exchange assay kit (Cytoskeleton, Inc.)
following the manufacturer's instructions. Briefly, this assay analyzes the
uptake of the fluorescent nucleotide analog N-methylanthraniloyl-GTP (mant-GTP)
into RHOA by measuring the spectroscopic difference between free and RHOA-bound
mant-GTP. As mant-GTP gets bound in the nucleotide binding pocket of RHOA in
response to a GEF protein, its fluorescence (ex: 360 nm, em: 440 nm) increases
dramatically. Thus, enhancement of mant-GTP fluorescent intensity in the
presence of RHOA indicates nucleotide uptake by the GTPase.</p></sec><sec id="S16"><title>RHOA activation assay</title><p id="P22">We used Jurkat cells expressing wild type HA&#x02013;RHOA, HA-RHOA
Gly17Val, HA-RHOA Thr19Asn and HA-RHOA Gln63Leu and plated them at
10<sup>6</sup> cells/ml in RPMI 0.5% FBS. After 24 hours we spun them down
and resuspended in serum-free RPMI 1640 media. For serum stimulation cells were
treated with media containing 10% FBS for 10 min. We washed serum starved and
serum stimulated cells once with ice cold PBS and lysed them in Lysis buffer (50
mM Tris pH 7.5, 10 mM MgCl<sub>2</sub>, 0.3 M NaCl and 2% IGEPAL). After
spinning down to remove debris and membranes we quantified lysate protein
content using the Precision Red Advanced Protein Assay (Cytoskeleton, Inc.).
Next we incubated 100 &#x003bc;g of total cleared protein lysate with 20
&#x003bc;l Rhotekin-RBD beads (Cystoskeleton, Inc.) for 1h at 4&#x000b0;C with
rotation. After incubation we washed the Rhotekin-RBD beads with 500 &#x003bc;l
wash buffer (25 mM Tris pH 7.5, 30 mM MgCl<sub>2</sub> and 40 mM NaCl),
resuspended them in 15 &#x003bc;l SDS-PAGE loading buffer. Rhotekin bead samples
were loaded into a Bis-Tris gel and proteins were resolved by electrophoresis in
MES buffer and transferred to a PVDF membrane. The presence of HA-tagged
activated RHOA associated with the Rhotekin-RBD beads was determined by
immunoblotting using an HA antibody following standard procedures.</p></sec><sec id="S17"><title>Immunoprecipitation and Western blot analysis of FYN activation</title><p id="P23">We performed FYN immunoprecipitations in Rat1A cells infected with
control (empty vector) retroviruses or retroviruses expressing wild type FYN,
FYN Leu174Arg, FYN Arg176Cys and FYN Tyr531His and analyzed FYN phosphorylation
via Western blot analysis using a Phospho-Src Family (Tyr416) polyclonal
antibody (#2101, Cell Signaling Technology).</p></sec><sec id="S18"><title>FYN protein expression in <italic>Escherichia coli</italic>, purification,
and peptide binding assays</title><p id="P24">We expressed wild type and mutant FYN SH2 domain as GST-tagged proteins
in <italic>E. coli</italic> Rosetta 2(DE3) cells as detailed for the production
of GST-RHOA fusion proteins before. Next, we performed peptide binding assays
with Pull-Down Biotinylated Protein-protein Interaction Kit (Thermo scientific)
according to the manufacturer's instructions using an amino acid 527-537 FYN
biotinylated peptide (biotin-Thr Glu Pro Gln Tyr Gln Pro Gly Glu Asn Leu); an
amino acid 527-537 pTyr531 FYN biotinylated peptide (biotin- Thr Glu Pro Gln
pTyr Gln Pro Gly Glu Asn Leu) and an amino acid 527-537 Tyr51His FYN
biotinylated peptide (biotin- Thr Glu Pro Gln His Gln Pro Gly Glu Asn Leu)
(Anaspec Inc). Briefly, we incubated synthetic biotinylated peptides with
purified GST-FYN SH2 domain, mutant FYN SH2 domain or GST alone proteins for 1 h
at 4&#x000b0;C, resolved and analyzed interacting proteins via 10%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by transfer to a PVDF
membrane and Western blot analysis with an anti-GST antibody.</p></sec><sec id="S19"><title>CSK FYN inhibition assay</title><p id="P25">We transfected Hela cells with plasmids driving expression of wild type
(pRK5 c-FYN) and activating mutant FYN alleles (pRK5 FYN Leu174Arg, pRK5 FYN
Arg176Cys and pRK5 FYN Tyr531His) alone and with a vector driving expression of
CSK (CSK-pcDNA3.1) at ratios 1:1 and 1:3 and analyzed the levels of FYN
activation and FYN and CSK expression via Western blot analysis.</p></sec><sec id="S20"><title>Dasatinib FYN inhibition assays</title><p id="P26">We transfected HEK293T cells with vectors driving the expression of
activated mutant FYN proteins (pRK5 FYN Leu174Arg, pRK5 FYN Arg176Cys and pRK5
FYN Tyr531His). After 48 hours cell cultures were treated with increasing
concentrations of dasatinib (Selleck Chemicals) for 6 hours and analyzed for FYN
phosphorylation and FYN expression by Western blot analysis. Similarly,
transformed Rat1A cells expressing the FYN Tyr531His mutant or a double FYN
Thr342Ile Tyr531His mutant protein were treated with vehicle only or dasatinib
(1&#x003bc;M) for 6 hours and analyzed for FYN phosphorylation and FYN expression
by Western blot analysis.</p></sec><sec id="S21"><title>Cell proliferation assays</title><p id="P27">We analyzed relative cell growth at 72 hours of vehicle only treated and
dasatinib treated (1&#x003bc;M) Rat1A transformed cells expressing either the FYN
Tyr531His mutant or a double FYN Thr342Ile Tyr531His mutant protein. Cell growth
was determined in triplicates by measurement of the metabolic reduction of the
tetrazolium salt MTT using the Cell Proliferation Kit I (Roche) following the
manufacturer's instructions.</p></sec><sec id="S22"><title>Statistical analyses</title><p id="P28">We evaluated differences in the percentages of <italic>RHOA</italic>
wild type and <italic>RHOA</italic> Gly17Val mutant in different PTCL groups
using the Fisher's exact test. We analyzed differences in cell growth rates in
control and dasatinib treated cells using the Student's <italic>t</italic> test.
We tested the linear correlation between tumor content in PTCL samples and
<italic>RHOA</italic> p.Gly17Val allele burden with the coefficient of
determination <italic>R<sup>2</sup>.</italic></p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>1</label><media xlink:href="NIHMS549899-supplement-1.pdf" orientation="portrait" xlink:type="simple" id="d37e1088" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>2</label><media xlink:href="NIHMS549899-supplement-2.xlsx" orientation="portrait" xlink:type="simple" id="d37e1092" position="anchor"/></supplementary-material></sec></body><back><ack id="S23"><title>ACKNOWLEDGEMENTS</title><p>This work was supported by a Leukemia &#x00026; Lymphoma Society Translational Research
Grant (A.F.), a Herbert Irving Comprehensive Cancer Center interprogrammatic pilot
project grant (A.F. &#x00026; R.R.), a National Institutes of Health Ruth L. Kirschstein
National Research Service Award (1F30CA174099 to J.E.H.), a grant from the Ligue
Nationale Contre le Cancer (O.B.) and an INCa-DHOS translational research grant
(O.B.). L.C. is a postdoctoral researcher funded by ITMO (Institut Multi Organismes
Cancer, France) and INCa (Institut National du Cancer, France). M.Y.K. is a
postdoctoral researcher funded by the Leukemia and Lymphoma Society. We would like
to thank Dr. Vincent Ribrag (Institut Gustave Roussy, Villejuif, France) for
providing a PTCL sample and Dr. Ramon Parsons (Mount Sinai School of Medicine, New
York, USA) for assistance in the set up of RHOA GTP loading assays.</p></ack><fn-group><fn id="FN1"><p id="P29">AUTHOR CONTRIBUTIONS</p><p id="P30">TP directed and supervised mutation analysis, performed functional
assays and wrote the manuscript; LC performed validation and recurrence mutation
analysis and functional assays; HK performed exome and RNAseq mutation analysis;
MYK performed peptide binding assays; AA analyzed Illumina deep sequencing
amplicon sequencing data; APG performed functional assays, ZC performed
structure function analysis and analyzed Illumina sequence data; FA performed
RNAseq mutation analysis and fusion oncogene identification; MA performed
validation analysis of Illumina sequencing results; JEH performed functional
assays; XJ performed functional assays; ISL contributed clinical samples and
supervised functional assays; CN, MB, CB, GB, MAP and EC contributed clinical
samples; OB designed the study, contributed samples and supervised research; RR
directed and supervised the analysis of Illumina sequencing data; AF designed
the study, directed and supervised research and wrote the manuscript.</p></fn><fn id="FN2"><p id="P31">Accession codes</p><p id="P32">Exome data and RNASeq data is available in dbGaP (access code
pending).</p><p id="P33">URLs</p><p id="P34">Primer 3 is available at <ext-link ext-link-type="uri" xlink:href="http://frodo.wi.mit.edu/primer3/">http://frodo.wi.mit.edu/primer3/</ext-link> and BWA-MEM at <ext-link ext-link-type="uri" xlink:href="http://bio-bwa.sourceforge.net">http://bio-bwa.sourceforge.net</ext-link></p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>JO</given-names></name></person-group><article-title>The aggressive peripheral T-cell lymphomas: 2012 update on
diagnosis, risk stratification, and management.</article-title><source>Am J Hematol</source><year>2012</year><volume>87</volume><fpage>511</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22508369</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudiger</surname><given-names>T</given-names></name><etal/></person-group><article-title>Peripheral T-cell lymphoma (excluding anaplastic large-cell
lymphoma): results from the Non-Hodgkin's Lymphoma Classification
Project.</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><fpage>140</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11863096</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>MR</given-names></name></person-group><article-title>Coupling receptor tyrosine kinases to Rho GTPases--GEFs what's
the link.</article-title><source>Cell Signal</source><year>2006</year><volume>18</volume><fpage>1834</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16725310</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar-Sagi</surname><given-names>D</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name></person-group><article-title>Ras and Rho GTPases: a family reunion.</article-title><source>Cell</source><year>2000</year><volume>103</volume><fpage>227</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">11057896</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vega</surname><given-names>FM</given-names></name><name><surname>Ridley</surname><given-names>AJ</given-names></name></person-group><article-title>Rho GTPases in cancer cell biology.</article-title><source>FEBS Lett</source><year>2008</year><volume>582</volume><fpage>2093</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">18460342</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanna</surname><given-names>S</given-names></name><name><surname>El-Sibai</surname><given-names>M</given-names></name></person-group><article-title>Signaling networks of Rho GTPases in cell
motility.</article-title><source>Cell Signal</source><year>2013</year></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>A</given-names></name></person-group><article-title>Rho family GTPases.</article-title><source>Biochem Soc Trans</source><year>2012</year><volume>40</volume><fpage>1378</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">23176484</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longenecker</surname><given-names>K</given-names></name><etal/></person-group><article-title>Structure of a constitutively activated RhoA mutant (Q63L) at
1.55 A resolution.</article-title><source>Acta Crystallogr D Biol Crystallogr</source><year>2003</year><volume>59</volume><fpage>876</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">12777804</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>T</given-names></name><name><surname>Meyer</surname><given-names>M</given-names></name><name><surname>Janning</surname><given-names>A</given-names></name><name><surname>Schiedel</surname><given-names>AC</given-names></name><name><surname>Barnekow</surname><given-names>A</given-names></name></person-group><article-title>A mutant form of the rho protein can restore stress fibers and
adhesion plaques in v-src transformed fibroblasts.</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>2117</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">10321736</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Rho family GTPases regulate p38 mitogen-activated protein kinase
through the downstream mediator Pak1.</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>23934</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7592586</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Role of RhoA activation in the growth and morphology of a murine
prostate tumor cell line.</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>4120</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10435593</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>ZK</given-names></name><etal/></person-group><article-title>Role of the Rho GTPase in bradykinin-stimulated nuclear
factor-kappaB activation and IL-1beta gene expression in cultured human
epithelial cells.</article-title><source>J Immunol</source><year>1998</year><volume>160</volume><fpage>3038</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">9510209</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>T</given-names></name><etal/></person-group><article-title>Rhotekin, a new putative target for Rho bearing homology to a
serine/threonine kinase, PKN, and rhophilin in the rho-binding
domain.</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>13556</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">8662891</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Mata</surname><given-names>R</given-names></name><etal/></person-group><article-title>Analysis of activated GAPs and GEFs in cell
lysates.</article-title><source>Methods Enzymol</source><year>2006</year><volume>406</volume><fpage>425</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">16472675</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couronne</surname><given-names>L</given-names></name><name><surname>Bastard</surname><given-names>C</given-names></name><name><surname>Bernard</surname><given-names>OA</given-names></name></person-group><article-title>TET2 and DNMT3A mutations in human T-cell
lymphoma.</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>95</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">22216861</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quivoron</surname><given-names>C</given-names></name><etal/></person-group><article-title>TET2 inactivation results in pleiotropic hematopoietic
abnormalities in mouse and is a recurrent event during human
lymphomagenesis.</article-title><source>Cancer Cell</source><year>2011</year><volume>20</volume><fpage>25</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">21723201</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cairns</surname><given-names>RA</given-names></name><etal/></person-group><article-title>IDH2 mutations are frequent in angioimmunoblastic T-cell
lymphoma.</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>1901</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">22215888</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palacios</surname><given-names>EH</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name></person-group><article-title>Function of the Src-family kinases, Lck and Fyn, in T-cell
development and activation.</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>7990</fpage><lpage>8000</lpage><pub-id pub-id-type="pmid">15489916</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCormack</surname><given-names>PL</given-names></name><name><surname>Keam</surname><given-names>SJ</given-names></name></person-group><article-title>Dasatinib: a review of its use in the treatment of chronic
myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic
leukaemia.</article-title><source>Drugs</source><year>2011</year><volume>71</volume><fpage>1771</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">21902298</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><article-title>Fast and accurate long-read alignment with Burrows-Wheeler
transform.</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>589</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">20080505</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>Fast gapped-read alignment with Bowtie 2.</article-title><source>Nat Methods</source><year>2012</year><volume>9</volume><fpage>357</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>R</given-names></name><etal/></person-group><article-title>Burkitt lymphoma pathogenesis and therapeutic targets from
structural and functional genomics.</article-title><source>Nature</source><year>2012</year><volume>490</volume><fpage>116</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">22885699</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maher</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Chimeric transcript discovery by paired-end transcriptome
sequencing.</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><fpage>12353</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19592507</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McPherson</surname><given-names>A</given-names></name><etal/></person-group><article-title>deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq
data.</article-title><source>PLoS Comput Biol</source><year>2011</year><volume>7</volume><fpage>e1001138</fpage><pub-id pub-id-type="pmid">21625565</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><etal/></person-group><article-title>UCSF Chimera--a visualization system for exploratory research and
analysis.</article-title><source>J Comput Chem</source><year>2004</year><volume>25</volume><fpage>1605</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altschul</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Gapped BLAST and PSI-BLAST: a new generation of protein database
search programs.</article-title><source>Nucleic Acids Res</source><year>1997</year><volume>25</volume><fpage>3389</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">9254694</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Kucukural</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>I-TASSER: a unified platform for automated protein structure and
function prediction.</article-title><source>Nat Protoc</source><year>2010</year><volume>5</volume><fpage>725</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">20360767</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subauste</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Rho family proteins modulate rapid apoptosis induced by cytotoxic
T lymphocytes and Fas.</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>9725</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">10734125</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariotti</surname><given-names>A</given-names></name><etal/></person-group><article-title>EGF-R signaling through Fyn kinase disrupts the function of
integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration
and carcinoma invasion.</article-title><source>J Cell Biol</source><year>2001</year><volume>155</volume><fpage>447</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">11684709</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamanova</surname><given-names>J</given-names></name><etal/></person-group><article-title>Adenylate cyclase toxin subverts phagocyte function by RhoA
inhibition and unproductive ruffling.</article-title><source>J Immunol</source><year>2008</year><volume>181</volume><fpage>5587</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">18832717</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallotta</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Indoleamine 2,3-dioxygenase is a signaling protein in long-term
tolerance by dendritic cells.</article-title><source>Nat Immunol</source><year>2011</year><volume>12</volume><fpage>870</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21804557</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harr</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Inhibition of Lck enhances glucocorticoid sensitivity and
apoptosis in lymphoid cell lines and in chronic lymphocytic
leukemia.</article-title><source>Cell Death Differ</source><year>2010</year><volume>17</volume><fpage>1381</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">20300113</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widmann</surname><given-names>C</given-names></name><name><surname>Gerwins</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>NL</given-names></name><name><surname>Jarpe</surname><given-names>MB</given-names></name><name><surname>Johnson</surname><given-names>GL</given-names></name></person-group><article-title>MEK kinase 1, a substrate for DEVD-directed caspases, is involved
in genotoxin-induced apoptosis.</article-title><source>Mol Cell Biol</source><year>1998</year><volume>18</volume><fpage>2416</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">9528810</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schenk</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sirt1 enhances skeletal muscle insulin sensitivity in mice during
caloric restriction.</article-title><source>J Clin Invest</source><year>2011</year><volume>121</volume><fpage>4281</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21985785</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Thrombin and lysophosphatidic acid receptors utilize distinct
rhoGEFs in prostate cancer cells.</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>28831</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15143072</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title><italic>RHOA</italic> mutations in PTCLs</title><p>(<bold>a</bold>) Schematic representation of the structure of the RHOA protein.
<italic>RHOA</italic> mutations identified by targeted amplicon resequencing
in PTCL samples are shown (n=64). Multiple circles in the same amino acid
position account for multiple patients with the same variant. (<bold>b</bold>)
Differential distribution of <italic>RHOA</italic> mutations in all PTCL
categories, PTCL NOS and AITLs. (<bold>c</bold>) Distribution of
<italic>RHOA</italic> p.Gly17Val, <italic>TET2</italic>,
<italic>DNMT3A</italic> and <italic>IDH2</italic> mutations in major PTCL
groups (AITL, n=30; PTCL NOS, n=17; ALCL ALK+, n=4; and ALCL ALKL&#x02013;, n=2).
Colored boxes indicate the presence of mutations in the indicated genes (rows)
in each patient sample (columns).</p></caption><graphic xlink:href="nihms-549899-f0001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Functional characterization of the RHOA Gly17Val protein</title><p>(<bold>a</bold>) GFP fluorescence micrographs of HEK293T cells expressing GFP,
GFP-RHOA, constitutively active GFP-RHOA Q63L, dominant negative GFP-RHOA
Thr19Asn and GFP-RHOA Gly17Val protein. Scale bar = 10&#x003bc;m.
(<bold>b</bold>) Immunofluorescence analysis of stress fiber formation in HeLa
cells expressing GFP, GFP-RHOA, GFP-RHOA Gln63Leu, GFP-RHOA Thr19Asn and
GFP-RHOA Gly17Val protein shown in green. Actin fibers stained with phalloidin
are shown in red and cell nuclei stained with DAPI are shown in blue. Scale bar
= 20&#x003bc;m. (<bold>c</bold>) Western blot analysis of GTP-bound HA-RHOA in
rhotekin pull downs from Jurkat cells expressing wild type HA-RHOA,
constitutively active HARHOA Gln63Leu, dominant negative HA-RHOA Thr19Asn and
the PTCL associated HA-RHOA Gly17Val protein. (<bold>d</bold>) Fluorescence
polarization analysis of mant-GTP loading to GST-RHOA, GST-RHOA Gly17Ala and
GST-RHOA Gly17Val in response to MCF2L/DBS stimulation. (<bold>c</bold>) Western
blot analysis of ARHGEF1 GEF protein pulled down with GST-RHOA, GST-RHOA
Gly17Ala and GST-RHOA Gly17Val from Jurkat cell lysates in basal conditions and
upon serum (FBS) stimulation. Pounceau S staining of bait protein loading is
shown at the bottom. Representative images from at least two independent
experiments are shown in (<bold>a</bold>) and (<bold>b</bold>). Data in
(<bold>d</bold>) shows average &#x000b1; s.d. from triplicate samples.</p></caption><graphic xlink:href="nihms-549899-f0002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title><italic>DNMT3A, TET2, IDH2, FYN, ATM, TET3, B2M</italic> and
<italic>CD58</italic> mutations in PTCLs</title><p><bold>a</bold>) Schematic representation of DNMT3A, TET2, TET3 and IDH2 proteins
showing DNA methylation and hydroxymethylation related mutations in PTCL
patients via exome sequencing (n=12) and amplicon resequencing (n=64).
<bold>b</bold>) Schematic representation of FYN, ATM, B2M and CD58 protein
variants identified in PTCL samples (n=12) and amplicon resequencing (n=64).
Solid circles indicate predicted amino acid substitutions. The position of
truncating mutations is indicated with red open circles. Multiple circles in the
same amino acid position account for multiple patients with the same
variant.</p></caption><graphic xlink:href="nihms-549899-f0003"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Structure modeling and functional characterization of <italic>FYN</italic>
mutations identified in PTCLs</title><p>(<bold>a</bold>) Analysis of FYN activation via phospho-SRC immunoblotting in
Rat1A cells infected wild type and PTCL associated FYN mutants expressing
retroviruses. (<bold>b</bold>) Analysis of FYN activation via phosphor-SRC
immunoblotting of FYN immunoprecipitates from Rat1A cells infected with wild
type and PTCL associated FYN mutants expressing retroviruses. (<bold>c</bold>)
Molecular ribbon representation of wild type FYN protein structure showing the
positioning of the FYN SH2 domain and the C terminal Tyr531 phosphosite.
(<bold>d</bold>) Structure modeling of FYN Tyr531His, FYN Arg176Cys and FYN
Leu174arg mutant proteins. (<bold>e</bold>) Analysis of wild type GSTSH2-FYN
interaction with C-terminal FYN peptides corresponding to wild type Tyr531 FYN,
wild type P-Tyr531 FYN and mutant Tyr531His FYN via Western blot analysis of
GST-SH2-FYN proteins in streptavidin-biotin C-terminal FYN peptide pull downs.
Experiment was replicated twice. (<bold>f</bold>) Analysis of P-Tyr531 FYN
C-terminal FYN peptide interaction with wild type GST-SH2-FYN and GST-SH2-FYN
Leu174Arg and GST-SH2-FYN Arg176Cys mutant proteins via Western blot analysis of
GST-SH2-FYN proteins in streptavidin-biotin P-Tyr531 C-terminal FYN peptide pull
downs. (<bold>g</bold>) Western blot analysis of CSK inhibition of FYN activity
in HeLa cells expressing wild type and PTCL associated FYN mutant proteins.
(<bold>h</bold>) Western blot analysis of dasatinib inhibition of FYN
activity in HEK293T cells expressing PTCL associated FYN mutant proteins.
(<bold>i, j</bold>) Analysis of dasatinib effects on FYN phosphorylation
(<bold>i</bold>) and relative cell growth (<bold>j</bold>) in transformed
Rat1A cells expressing the constitutively active FYN Tyr531His or the
dasatinib-resistant FYN Thr342Ile Tyr531His double mutant protein. Data in
(<bold>j</bold>) shows average &#x000b1; s.d. from triplicate samples.
<italic>P</italic> values were calculated using the two-tailed Student's
<italic>t</italic> test.</p></caption><graphic xlink:href="nihms-549899-f0004"/></fig></floats-group></article>